文献速递白血病

MTSS1下调与急性髓系白血病不良预后、化疗耐药及疾病侵袭性相关

Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness.
PubMed 文献 · Leukemia · 2021-03-29

该研究基于前期发现的AML诊断与复发间差异表达基因MTSS1,探讨其在AML中的作用。结果显示诊断时MTSS1低表达与不良预后相关,其表达受启动子甲基化调控并可被阿糖胞苷和柔红霉素降低。实验性下调MTSS1诱导WEE1表达,使AML细胞系对化疗药物更耐药,并在小鼠MLL-AF9驱动AML中缩短疾病潜伏期、增加白血病负荷和体外化疗耐药。

要点

  • 诊断时MTSS1低表达与AML不良预后相关。
  • MTSS1表达受启动子甲基化调控,且被阿糖胞苷和柔红霉素降低。
  • 下调MTSS1诱导WEE1并增强AML细胞对化疗药物的耐药性。

核心结论

  • 低MTSS1表达是AML疾病侵袭性、治疗耐药和不良预后的新影响因素。

研究设计与样本

  • 基于前期鉴定诊断与复发间差异表达基因的研究,对人AML细胞系和小鼠MLL-AF9驱动AML模型进行实验性MTSS1下调研究。

主要发现

  • 诊断时低MTSS1表达与AML不良预后相关。
  • MTSS1表达受启动子甲基化调控,并被阿糖胞苷和柔红霉素降低。
  • 实验性下调MTSS1影响众多基因表达,诱导DNA损伤应答激酶WEE1。
  • 下调MTSS1使人类AML细胞系对阿糖胞苷、柔红霉素及其他抗癌药物更耐药。
  • 小鼠MLL-AF9驱动AML中敲低Mtss1显著缩短疾病潜伏期,增加白血病负荷和体外化疗耐药。

临床怎么用

  • 诊断时MTSS1低表达可能提示AML患者预后不良和化疗耐药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite recent approval of targeted drugs for acute myeloid leukemia (AML) therapy, chemotherapy with cytosine arabinoside and anthracyclines remains an important pillar of treatment. Both primary and secondary resistance are frequent and associated with poor survival, yet the underlying molecular mechanisms are incompletely understood. In previous work, we identified genes deregulated between diagnosis and relapse of AML, corresponding to therapy naïve and resistant states, respectively. Among them was MTSS1, whose downregulation is known to enhance aggressiveness of solid tumors. Here we show that low MTSS1 expression at diagnosis was associated with a poor prognosis in AML. MTSS1 expression was regulated by promoter methylation, and reduced by cytosine arabinoside and the anthracycline daunorubicin. Experimental downregulation of MTSS1 affected the expression of numerous genes. It induced the DNA damage response kinase WEE1, and rendered human AML cell lines more resistant to cytosine arabinoside, daunorubicin, and other anti-cancer drugs. Mtss1 knockdown in murine MLL-AF9-driven AML substantially decreased disease latency, and increased leukemic burden and ex vivo chemotherapy resistance. In summary, low MTSS1 expression represents a novel factor contributing to disease aggressiveness, therapy resistance, and poor outcome in AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Grandits AM, Nguyen CH, Schlerka A, et al. Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness. Leukemia. 2021. PMID: 33782537. doi:10.1038/s41375-021-01224-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。